233 related articles for article (PubMed ID: 33055223)
1. The Influence of Tobacco Smoke/Nicotine on CYP2A Expression in Human and African Green Monkey Lungs.
Gao Y; Miksys S; Palmour RM; Tyndale RF
Mol Pharmacol; 2020 Dec; 98(6):658-668. PubMed ID: 33055223
[TBL] [Abstract][Full Text] [Related]
2. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
3. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
4. CYP2A6 polymorphisms and risk for tobacco-related cancers.
Rossini A; de Almeida Simão T; Albano RM; Pinto LF
Pharmacogenomics; 2008 Nov; 9(11):1737-52. PubMed ID: 19018727
[TBL] [Abstract][Full Text] [Related]
5. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
6. Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa.
Chen Y; Liu YQ; Su T; Ren X; Shi L; Liu D; Gu J; Zhang QY; Ding X
Biochem Pharmacol; 2003 Oct; 66(7):1245-51. PubMed ID: 14505803
[TBL] [Abstract][Full Text] [Related]
7. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
Schoedel KA; Sellers EM; Palmour R; Tyndale RF
Mol Pharmacol; 2003 Jan; 63(1):96-104. PubMed ID: 12488541
[TBL] [Abstract][Full Text] [Related]
9. Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.
Blake LC; Roy A; Neul D; Schoenen FJ; Aubé J; Scott EE
Pharm Res; 2013 Sep; 30(9):2290-302. PubMed ID: 23756756
[TBL] [Abstract][Full Text] [Related]
10. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
DeVore NM; Scott EE
J Biol Chem; 2012 Aug; 287(32):26576-85. PubMed ID: 22700965
[TBL] [Abstract][Full Text] [Related]
11. Expression of CYP2A genes in human liver and extrahepatic tissues.
Koskela S; Hakkola J; Hukkanen J; Pelkonen O; Sorri M; Saranen A; Anttila S; Fernandez-Salguero P; Gonzalez F; Raunio H
Biochem Pharmacol; 1999 Jun; 57(12):1407-13. PubMed ID: 10353262
[TBL] [Abstract][Full Text] [Related]
12. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
Yuan JM; Nelson HH; Carmella SG; Wang R; Kuriger-Laber J; Jin A; Adams-Haduch J; Hecht SS; Koh WP; Murphy SE
Carcinogenesis; 2017 Apr; 38(4):411-418. PubMed ID: 28182203
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys.
Ferguson CS; Miksys S; Palmour RM; Tyndale RF
J Pharmacol Exp Ther; 2012 Dec; 343(3):628-37. PubMed ID: 22935730
[TBL] [Abstract][Full Text] [Related]
14. CYP2A6: genetics, structure, regulation, and function.
Raunio H; Rahnasto-Rilla M
Drug Metabol Drug Interact; 2012 May; 27(2):73-88. PubMed ID: 22706231
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Tyndale RF; Sellers EM
Ther Drug Monit; 2002 Feb; 24(1):163-71. PubMed ID: 11805739
[TBL] [Abstract][Full Text] [Related]
16. Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort study.
Park SL; Murphy SE; Wilkens LR; Stram DO; Hecht SS; Le Marchand L
PLoS One; 2017; 12(5):e0178435. PubMed ID: 28542511
[TBL] [Abstract][Full Text] [Related]
17. Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse.
Li L; Jia K; Zhou X; McCallum SE; Hough LB; Ding X
J Pharmacol Exp Ther; 2013 Dec; 347(3):746-54. PubMed ID: 24045421
[TBL] [Abstract][Full Text] [Related]
18. Structure of the human lung cytochrome P450 2A13.
Smith BD; Sanders JL; Porubsky PR; Lushington GH; Stout CD; Scott EE
J Biol Chem; 2007 Jun; 282(23):17306-13. PubMed ID: 17428784
[TBL] [Abstract][Full Text] [Related]
19. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
[TBL] [Abstract][Full Text] [Related]
20. Suppression of pulmonary CYP2A13 expression by carcinogen-induced lung tumorigenesis in a CYP2A13-humanized mouse model.
Liu Z; Megaraj V; Li L; Sell S; Hu J; Ding X
Drug Metab Dispos; 2015 May; 43(5):698-702. PubMed ID: 25710941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
